|
Premier Research Group Limited, the international pharmaceutical and medical device services company, announces the appointments of two physicians, Dr. Patricia Taylor Molloy and Dr. Michael H. Skinner, to their Medical Affairs and Strategic Consulting Group. The addition of these clinicians will significantly enhance Premier Research‘s expertise, particularly in the areas of neurology, oncology, pediatrics, and analgesia.
Patricia Molloy, MD has been appointed to the position of Vice President, Global Medical Affairs and Strategic Consulting. In this role, she will be responsible for global oversight of Medical Affairs and Strategic Consulting. Dr. Molloy brings more than 18 years of research experience with extensive late stage clinical development expertise in oncology, neurology and pediatrics. Dr. Molloy was most recently Senior Medical Director, Oncology and Neurology at Cephalon, and has held previous positions in oncology and neurology research at Kyowa Pharmaceuticals, ImClone Systems, and Allergan. She is a board certified neurologist with a fellowship in neuro-oncology.
Michael H. Skinner, MD, PharmD has been appointed as an Executive Director, Medical Affairs and Strategic Consulting. Dr. Skinner will provide consulting, strategic development and medical monitoring services in the areas of internal medicine and analgesia. Dr. Skinner brings to Premier Research more than 12 years of pharmaceutical experience. His prior experience includes senior level positions at a number of pharmaceutical and biotechnology companies, most recently as the Senior Medical Director at Somaxon Pharmaceuticals and Vice President Clinical Development at Allergan, Inc. Prior to that, Dr. Skinner has held positions at Neurocrine Biosciences and Eli Lilly & Co. He is a board certified in internal medicine and clinical pharmacology with fellowships clinical pharmacology and substance abuse.
“Each appointment brings medical expertise, strong clinical knowledge, leadership, and a wealth of experience in key areas that are of importance for our clients and will provide an added level of therapeutic insight to Premier Research’s service offerings,” said James Ottinger, Vice President, Global Consulting and Compliance. “They are welcome additions to our team.” |
|